This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2018 Dec 1;79(4):e111.

doi: 10.1097/QAI.0000000000001892.

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate: Erratum

No authors listed

PMID: 30365453
DOI: 10.1097/QAI.0000000000001892

Published Erratum

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate: Erratum

No authors listed. J Acquir Immune Defic Syndr. 2018.

. 2018 Dec 1;79(4):e111.

doi: 10.1097/QAI.0000000000001892.

PMID: 30365453
DOI: 10.1097/QAI.0000000000001892

No abstract available

PubMed Disclaimer

Erratum for

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.
Andreatta K, Chang S, Martin R, Acosta R, Daeumer M, Thielen A, Miller MD, White KL. Andreatta K, et al. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e45-e51. doi: 10.1097/QAI.0000000000001757. J Acquir Immune Defic Syndr. 2018. PMID: 29781878 No abstract available.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer